

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

APPOINTMENT OF EXECUTIVE DIRECTOR; RESIGNATION AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS; CHANGES IN COMPOSITION OF THE AUDIT COMMITTEE; AND CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The board (the “**Board**”) of directors (the “**Directors**”) of China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the following appointment of executive Director, resignation and appointment of independent non-executive Directors, changes in the composition of the audit committee of the Company (the “**Audit Committee**”) and change of company secretary and authorised representative of the Company.

APPOINTMENT OF EXECUTIVE DIRECTOR

Dr. Yin Ye (尹燁) (“**Dr. Yin**”) has been appointed as an executive Director with effect from 25 July 2025.

The biographical details of Dr. Yin are set out below:

Dr. Yin, aged 45, is the chief executive officer and executive director of the BGI Group, where he leads the teams to actively promote the industrial application of cutting-edge biotechnology and genomics research and works. He joined the BGI Group in 2002 and has served various positions within the group since then. He has served as a director and the vice president of BGI Genomics Co., Ltd. (a company listed on the Shenzhen Stock Exchange with stock code: 300676.SZ) (“**BGI Genomics**”) until June 2024, the general manager of BGI Genomics, the general manager of BGI Medicine Co., Ltd.* (深圳華大基因醫學有限公司), the chief operating officer of Shenzhen BGI Technology Limited* (深圳華大基因科技有限公司), etc.

Dr. Yin obtained a bachelor's degree in bioengineering from Dalian University of Technology in 2002, a master's degree in bioengineering from South China University of Technology in 2013, and a PhD degree in Biology from the University of Copenhagen in 2019. He has also been certified by the BGI Genomics advanced professional and technical qualification assessment committee as a genomics researcher.

Pursuant to the letter of appointment made between Dr. Yin and the Company, Dr. Yin has been appointed for a term of three years commencing from 25 July 2025 unless terminated by one month's prior written notice given by either party to the other and is subject to retirement by rotation and re-election and other related provisions as stipulated in the bye-laws of the Company and the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**GEM Listing Rules**"). Pursuant to the bye-laws of the Company, Dr. Yin shall hold office until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election at the meeting and thereafter, shall be subject to retirement by rotation at least once every three years. Pursuant to the letter of appointment, Dr. Yin is entitled to a director's fee of HK\$50,000 per month, which was determined by the Board on the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities, the remuneration policy of the Company as well as the prevailing market conditions. He is also entitled to discretionary bonus, share options under share options scheme and share awards under the share award scheme to be determined by the Board with reference to his performance and the performance of the Group.

As at the date of this announcement, save as disclosed above, Dr. Yin (i) does not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, or any other major appointments and professional qualifications; (ii) does not hold any other positions with the Company or other members of the Group; (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meaning ascribed to it in the GEM Listing Rules) of the Company; (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) has not been involved in any of the matters as mentioned under Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

Save as disclosed in this announcement, there is no further information to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules and there are no other matters relating to the appointment of Dr. Yin that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Dr. Yin to join the Board.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

Mr. Qian Hongji (“**Mr. Qian**”) has tendered his resignation as an independent non-executive Director and a member of the Audit Committee with effect from 25 July 2025 due to other business commitments which require more of his dedication. Mr. Qian has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company. The Board would like to take this opportunity to express its sincere gratitude to Mr. Qian for his valuable contributions to the Company during his tenure of service.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

Dr. Zhang Xiao (張曉) (“**Dr. Zhang**”) has been appointed as an independent non-executive Director and a member of the Audit Committee with effect from 25 July 2025.

The biographical details of Dr. Zhang are set out below:

Dr. Zhang, aged 63, was the global senior vice president and president of Greater China of Varian Medical Systems before his retirement in 2024. He joined Varian Medical Systems in 2013 as the managing director of China, responsible for the business of radiotherapy, proton therapy and its X-ray imaging components in China. In 2014, he was appointed as the global vice president and president of Greater China of Varian, responsible for the business in Mainland China and Taiwan. Under his leadership, Varian’s business continued to grow and had taken a leading position in the Greater China market. Dr. Zhang was committed to expanding the accessibility of tumor radiotherapy in China and improving the five-year survival rate of Chinese cancer patients. He has driven a series of transformative and innovative initiatives for Varian in China, including the launch of Halcyon, a next-generation intelligent radiotherapy platform, the application of advanced technologies such as artificial intelligence to create a comprehensive radiotherapy cloud solution, etc. Prior to joining Varian, he had worked in different business groups of General Electric.

Dr. Zhang obtained a Master of Science and a Doctor of Philosophy from the University of Tennessee, Knoxville in 1989 and 1992 respectively.

Pursuant to the letter of appointment made between Dr. Zhang and the Company, Dr. Zhang has been appointed as an independent non-executive Director for a term of one year commencing from 25 July 2025 unless terminated by one month's prior written notice given by either party to the other and is subject to retirement by rotation and re-election and other related provisions as stipulated in the bye-laws of the Company and GEM Listing Rules. Pursuant to the bye-laws of the Company, Dr. Zhang shall hold office until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election at the meeting and thereafter, shall be subject to retirement by rotation at least once every three years. Pursuant to the letter of appointment, Dr. Zhang is entitled to a director's fee of HK\$20,000 per month, which was determined by the Board on the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities, the remuneration policy of the Company as well as the prevailing market conditions.

As at the date of this announcement, save as disclosed above, Dr. Zhang (i) does not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, or any other major appointments and professional qualifications; (ii) does not hold any other positions with the Company or other members of the Group; (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company; (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) has not been involved in any of the matters as mentioned under Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

Dr. Zhang has also confirmed that (i) he meets the independence criteria as set out in Rule 5.09 of the GEM Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the GEM Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there is no other information to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules and there are no other matters relating to the appointment of Dr. Zhang that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Dr. Zhang to join the Board.

CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

In order to devote more time to his other commitments, Mr. Lam Tak Ming (“**Mr. Lam**”) resigned as the company secretary of the Company (“**Company Secretary**”) and one of the authorised representatives of the Company (“**Authorised Representative**”) for the purpose of Rule 5.24 of the GEM Listing Rules with effect from 25 July 2025. Mr. Lam confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the Stock Exchange and shareholders of the Company.

The Board is pleased to announce that Ms. Fung Pui Yin (“**Ms. Fung**”), the Financial Controller of the Company, has been appointed as the Company Secretary and an Authorised Representative with effect from 25 July 2025. Ms. Fung holds a bachelor’s degree in accountancy from The Hong Kong Polytechnic University and is a member of CPA Australia. She has over 7 years of accounting and auditing experience at an international accounting firm.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Lam for his invaluable contribution and services during his tenure of office and welcome Ms. Fung to her new appointment.

By order of the Board
China Biotech Services Holdings Limited
Chairman and Executive Director
Liu Xiaolin

Hong Kong, 25 July 2025

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.

* *The English transliteration of the Chinese name is for identification purpose only. If there is any inconsistency, the Chinese name shall prevail.*